JP2013539778A5 - - Google Patents

Download PDF

Info

Publication number
JP2013539778A5
JP2013539778A5 JP2013533265A JP2013533265A JP2013539778A5 JP 2013539778 A5 JP2013539778 A5 JP 2013539778A5 JP 2013533265 A JP2013533265 A JP 2013533265A JP 2013533265 A JP2013533265 A JP 2013533265A JP 2013539778 A5 JP2013539778 A5 JP 2013539778A5
Authority
JP
Japan
Prior art keywords
cancer
composition according
composition
mol
vgsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013533265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013539778A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2010/001908 external-priority patent/WO2012049440A1/en
Publication of JP2013539778A publication Critical patent/JP2013539778A/ja
Publication of JP2013539778A5 publication Critical patent/JP2013539778A5/ja
Pending legal-status Critical Current

Links

JP2013533265A 2010-10-13 2010-10-13 癌の治療/転移の阻害 Pending JP2013539778A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2010/001908 WO2012049440A1 (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016019817A Division JP6465306B2 (ja) 2016-02-04 2016-02-04 癌の治療/転移の阻害

Publications (2)

Publication Number Publication Date
JP2013539778A JP2013539778A (ja) 2013-10-28
JP2013539778A5 true JP2013539778A5 (https=) 2013-12-05

Family

ID=44022817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013533265A Pending JP2013539778A (ja) 2010-10-13 2010-10-13 癌の治療/転移の阻害

Country Status (13)

Country Link
US (5) US20130203764A1 (https=)
EP (4) EP2627321A1 (https=)
JP (1) JP2013539778A (https=)
KR (1) KR20140032346A (https=)
CN (2) CN112755029A (https=)
AU (2) AU2010362412A1 (https=)
BR (1) BR112013009086A2 (https=)
CA (1) CA2851694C (https=)
DK (1) DK3132791T3 (https=)
IL (1) IL225689A0 (https=)
RU (1) RU2013121744A (https=)
SG (1) SG189352A1 (https=)
WO (1) WO2012049440A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013009086A2 (pt) 2010-10-13 2016-07-26 Mustafa Bilgin Ali Djamgoz tratamento de câncer/inibição de metástase
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
WO2017091574A1 (en) * 2015-11-25 2017-06-01 Health Research, Inc. Riluzole and riluzole drug combinations for the treatment of prostate cancer
JP6465306B2 (ja) * 2016-02-04 2019-02-06 セレックス・オンコロジー・リミテッド 癌の治療/転移の阻害
LT3458053T (lt) * 2016-05-20 2022-02-25 Biohaven Pharmaceutical Holding Company Ltd. Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
AU2018218341B2 (en) * 2017-02-10 2023-07-06 Celex Oncology Innovations Limited Treatment of cancer and inhibition of metastasis
US20200123544A1 (en) * 2018-10-22 2020-04-23 Celex Oncology Innovations Limited Gene therapy targeting the neonatal form of nav1.5 for treating cancer
AU2020370748B2 (en) * 2019-10-24 2025-08-21 Celex Oncology Innovations Limited Combination treatments for cancer
US20230062361A1 (en) 2020-01-21 2023-03-02 Celex Oncology Innovations Limited Monoclonal antibodies against neonatal nav1.5
US20230139204A1 (en) 2020-03-09 2023-05-04 Celex Oncology Innovations Limited Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells
EP4176880A4 (en) * 2020-07-01 2024-07-03 New Cancer Cure - Bio Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER COMPRISING A 3-KETOACYL-COA THIOLASE INHIBITOR AND AN INHIBITOR OF CARNITINE ACYLCARNITINE TRANSPORTERS
AU2024357729A1 (en) 2023-10-12 2026-04-09 Celex Oncology Innovations Limited Treatment of metastatic or invasive brain cancer
WO2025252860A1 (en) 2024-06-04 2025-12-11 Celex Oncology Innovations Limited Ranolazine enantiomer for use in cancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088915A2 (en) * 2002-04-18 2003-10-30 University Of Virginia Patent Foundation Novel sodium channel blockers
WO2004062604A2 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US8835473B2 (en) * 2004-04-16 2014-09-16 Rutgers, The State University Of New Jersey Methods and compositions for treating cancer
ES2691411T3 (es) 2006-03-27 2018-11-27 Wex Medical Limited Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
WO2010033581A1 (en) * 2008-09-16 2010-03-25 University Of Washington Molecular modulators of the wnt/beta-catenin pathway
BR112013009086A2 (pt) * 2010-10-13 2016-07-26 Mustafa Bilgin Ali Djamgoz tratamento de câncer/inibição de metástase

Similar Documents

Publication Publication Date Title
JP2013539778A5 (https=)
CL2011002384A1 (es) Composicion parasiticida topica que comprende un insecticida tipo fenilpirasol y/o un neonicotinoide, una lactona macrociclica y/o un derivado de aminoacetonitrilo, un regulador del crecimiento de insectos y un derivado de 2-acil-4-axo-1,2,3,6,7,11b-4h-pirazino [2,1a] isoquinolina.
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
CO7101251A2 (es) Derivado de sulfuro de alquil fenilo y agente de control de plagas
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
PL3061454T3 (pl) Pasożytobójcze doustne kompozycje weterynaryjne obejmujące systemowo działające środki aktywne, sposoby i ich zastosowania
BR112016000194A8 (pt) forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
ECSP13013007A (es) Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
MX2010001574A (es) Ligandos del receptor cannabinoide.
IN2014DN09571A (https=)
EP4640281A3 (en) Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel
PE20081751A1 (es) Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor
NZ626575A (en) Aryloxyurea compound and pest control agent
MX2012000962A (es) Composicion para controlar plagas.
PH12013501549A1 (en) Oral care compositions
UA107418C2 (en) Harvesting attachment for a harvester
EP2575842A4 (en) COMPOSITION COMPRISING THE EXTRACT OF PHYSALIS ALKEKENGI VAR. FRANCHETI HORT AS AN ACTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
WO2014062228A8 (en) An improved nanovector based drug delivery system for overcoming drug resistance
UA111324C2 (uk) Агент для профілактики або зменшення пігментації
MX378261B (es) Formas de dosificación sólidas de liberación prolongada antieméticas.
CL2008001973A1 (es) Derivados de macrolactonas de formula (i) con actividad antifuga, partucularmente contra c.albicans; el metodo para producur dichas macra lactonas a partir de una cepa de myxobacterium sp., y el uso de dichas macaralactonas en la elaboracion d medicamentos antifungicos que la contiene